Immune Responsiveness of Human Tumours

Immunogenomics and Human Disease

Volumn , Issue , 2006, Pages 133-151

  Wang, Ena ^a   Marincola, Francesco M ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Active specific vaccination; Basal cell carcinoma (BCC); Hypothesis driven research; Hypothesis generating methods; Immune editing; Immune responsiveness; Toll receptor ligands; Tumour immune responsiveness; Tumour infiltrating lymphocytes

Indexed keywords

EID: 84889844748     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470034092.ch7     Document Type: Chapter

References (92)

1. Abgrall S, Orbach D, Bonhomme-Faivre L, Orbach-Arbouys S. 2002. Tumors in organ transplant recipients may give clues to their control by immunity. Anticancer Res 22(6B): 3597-3604.
2. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Bedrick JC, Sabet H, Tran T, Xin Y, Powell JI, Yang L, Marti GE, Moore T, Hudson J Jr. , Lisheng L, Lewis DB, Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO, Staudt LM. 2000. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403: 467-578.
3. Atkins MB, Regan M, McDermott D. 2004. Update on the role of interleukin 2 and other cytokines in the treatment of patients with stage IV renal carcinoma. Clin Cancer Res 10(18 Pt 2): 6342S-6346S.
4. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson DR, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. 1998. High-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 17(7): 2105-2116.
5. Bex A, Horenblas S, Meinhardt W, Verra N, de Gast GC. 2002. The role of initial immunotherapy as selection for nephrectomy in patients with metastatic renal cell carcinoma and the primary tumour in situ. Eur Urol 42(6): 570-574.
6. Bittner M, Meltzer P, Chen Y, Jiang E, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Dougherty E, Wang E, Marincola FM, Gooden C, Lueders J, Glatfelter A, Pollock P, Gillanders E, Dietrich K, Alberts D, Sondak VK, Hayward N, Trent JM. 2000. Molecular classification of cutaneous malignant melanoma by gene expression: shifting from a countinuous spectrum to distinct biologic entities. Nature 406: 536-840.
7. Boer JM, Huber WK, Sultmann H, Wilmer F, von Heydebreck A, Haas S, Korn B, Gunawan B, Vente A, Fuzesi L, Vingron M, Poustka A. 2001. Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31, 500-element cDNA array. Genome Res 11(11): 1861-1870.
8. Brinckerhoff LH, Thompson LW, Slingluff CL Jr. 2000. Melanoma vaccines. Curr Opin Oncol 12(2): 163-173.
9. Bui MH, Seligson D, Han KR, Pantuck AJ, Dorey FJ, Huang Y, Horvath S, Leibovich BC, Chopra S, Liao SY, Stanbridge E, Lerman MI, Palotie A, Figlin RA, Belldegrun AS. 2003. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 9(2): 802-811.
10. Burnet FM. 1970. The concept of immunological surveillance. Prog Exp Tumor Res 13: 1-27.
11. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, Rosenberg SA, Marincola FM. 1997. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. [See comments. ] Cancer J Sci Am 3(1): 37-44.
12. Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL. 1998a. Comparative analysis of the in vivo expression of tyrosinase, MART-1/Melan-A, and gp100 in metastatic melanoma lesions: implications for immunotherapy. J Immunother 21(1): 27-31.
13. Cormier JN, Hijazi YM, Abati A, Fetsch P, Bettinotti M, Steinberg SM, Rosenberg SA, Marincola FM. 1998b. Heterogeneous expression of melanoma-associated antigens (MAA) and HLA-A2 in metastatic melanoma in vivo. Int J Cancer 75: 517-524.
14. Cottrill CP, Bottomley DM, Phillips RH. 1997. Cancer and HIV infection. Clin Oncol (R Coll Radiol) 9(6): 365-380.
15. Dunn GP, Old LJ, Schreiber RD. 2004. The three Es of cancer immunoediting. A Rev Immunol 22: 329-360.
16. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. 2002. Cancer immunoediting: from immunosurveillance to tumour escape. Nat Immunol 3(11): 991-998.
17. Ellis MJ. 2003. Breast cancer gene expression analysis-the case for dynamic profiling. Adv Exp Med Biol 532: 223-234.
18. el-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L. 1999. MHC class I-restricted epitope spreading in the context of tumour rejection following vaccination with a single immiunodominant epitope. Eur J Immunol 29(10): 3295-3301.
19. Euvrard S, Ulrich C, Lefrancois N. 2004. Immunosuppressants and skin cancer in transplant patients: focus on rapamycin. Dermatol Surg 30(4 Pt 2): 628-633.
20. Fuchs EJ, Matzinger P. 1996. Is cancer dangerous to the immune system? Sem Immunol 8(5): 271-280.
21. Grulich AE. 2000. Update: cancer risk in persons with HIV/AIDS in the era of combination antiretroviral therapy. AIDS Read 10(6): 341-346.
22. Hicklin DJ, Marincola FM, Ferrone S. 1999. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 5(4): 178-186.
23. Howell WM, Calder PC, Grimble RF. 2002. Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc 61(4): 447-456.
24. Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. 2002. Influence of vascular endothelial growth factor single nucleotide polymorphisms on tumour development in cutaneous malignant melanoma. Genes Immun 3: 229-232.
25. Itoh K, Tilden AB, Balch CM. 1986. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res, 46(6): 3011-3017.
26. Jager E, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. 1996. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8{thorn} cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66(4): 470-476.
27. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F, Knuth A. 1997. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71(2): 142-147.
28. Jin P. Wang E. 2003. Polymorphism in clinical immunology. From HLA typing to immunogenetic profiling. J Transl Med 1: 8.
29. Jin P, Marincola FM, Wang E. 2004. Cytokine polymorphism and its possible impact on cancer. Immunol Res 30(2): 181-190.
30. Kammula US, Lee K-H, Riker A, Wang E, Ohnmacht GA, Rosenberg SA, Marincola FM. 1999. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumour specimens. J Immunol 163: 6867-6879.
31. Kawakami Y, Zakut R, Topalian SL, Stotter H, Rosenberg SA. 1992. Shared human melanoma antigen. Recognition by tumor-infiltrating lymphocytes in HLA-A2. 1-transfected melanomas. J Immunol 148: 638-643.
32. Khong HT. Restifo NP. 2002. Natural selection of tumour variants in the generation of ''tumor escape'' phenotypes. Nat Immunol 3(11): 999-1005.
33. Klein CA. 2003. The systemic progression of human cancer: a focus on the individual disseminated cancer cell-the unit of selection. Adv Cancer Res 89: 35-67.
34. Klein CA. 2004. Gene expression sigantures, cancer cell evolution and metastatic progression. Cell Cycle 3(1): 29-31.
35. Lally KM, Mocellin S, Ohnmacht GA, Nielsen M-B, Bettinotti M, Panelli MC, Monsurro' V, Marincola FM. 2001. Unmasking cryptic epitopes after loss of immunodominant tumour antigen expression through epitope spreading. Int J Cancer 93: 841-847.
36. Lee JE, Reveille JD, Ross MI, Platsoucas CD. 1994. HLA-DQB1*0301 association with increased cutaneous melanoma risk. Int J Cancer 59(4): 510-513.
37. Lee K-H, Panelli MC, Kim CJ, Riker A, Roden M, Fetsch PA, Abati A, Bettinotti MP, Rosenberg SA, Marincola FM. 1998. Functional dissociation between local and systemic immune response following peptide vaccination. J Immunol 161: 4183-4194.
38. Lee K-H, Wang E, Nielsen M-B, Wunderlich J, Migueles S, Connors M, Steinberg SM, Rosenberg SA, Marincola FM. 1999. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumour regression. J Immunol 163: 6292-6300.
39. Lengauer C, Kinzler KW, Vogelstein B. 1998. Genetic instabilities in human cancers. Nature 396(6712): 643-649.
40. Londono-Vallejo, JA. 2004. Telomere length heterogeneity and chromosome instability. Cancer Lett 212(2): 135-144.
41. Lutz J, Heemann U. 2003. Tumours after kidney transplantation. Curr Opin Urol 13(2): 105-109.
42. Mankoff SP, Brander C, Ferrone S, Marincola FM. 2004. Lost in translation: obstacles to Translational Medicine. J Transl Med 2(1): 14.
43. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. 2002. Macrophage polarization: tumorassociated macrophage as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23(11): 549-555.
44. Marincola FM. 2003. Translational medicine: a two way road. J Transl Med 1: 1.
45. Marincola FM. 2005. A balanced review of the status of T cell-based therapy against cancer. J Transl Med 3: 16.
46. Marincola FM, Ferrone, S. 2003. Immunotherapy of melanoma: the good news, the bad news and what to do next. Sem Cancer Biol 13(6): 387-389.
47. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov SA, Simonis TB, Taubenberger JK, Yannelli J, Mixon A, Restito NP, Herlyn M, Rosenberg SA. 1994. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J Immunol 153: 1225-1237.
48. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier JN, Simonis TB, Duray PH, Herlyn M, Kawakami Y, Rosenberg SA. 1996a. Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J Immunother 19(3): 192-205.
49. Marincola FM, Shamamian P, Rivoltini L, Salgaller ML, Reid J, Restifo NP, Simonis TB, Venzon D, White DE, Parkinson DR. 1996b. HLA associations in the anti-tumor response against malignant melanoma. J Immunother 18: 242-252.
50. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. 2003. Tumors as elusive targets of T celldirected immunotherapy. Trends Immunol 24(6): 334-341.
51. Matzinger P. 2001. Danger model of immunity. Scand J Immunol 54(1-2): 2-3.
52. Mocellin S, Mandruzzato S, Bronte V, Marincola FM. 2004. Correspondence 1: Cancer vaccines: pessimism in check. Nat Med 10(12): 1278-1279.
53. Monsurro' V, Wang E, Yamano Y, Migueles SA, Panelli MC, Smith K, Nagorsen D, Connors M, Jacobson S, Marincola FM. 2004. Quiescent phenotype of tumor-specific CD8{thorn} T cells following immunization. Blood 104(7): 1970-1978.
54. Nagorsen D, Wang E, Monsurro' V, Zanovello P, Marincola FM, and Panelli MC. 2004. Polarized monocyte response to cytokine stimulation. Genome Biol 6(2): R15.
55. Novellino L, Castelli C, Parmiani G. 2004. A listing of human tumour antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother 54(3): 187-207.
56. Ohnmacht GA, Wang E, Mocellin S, Abati A, Filie A, Fetsch PA, Riker A, Kammula US, Rosenberg SA, Marincola FM. 2001. Short term kinetics of tumour antigen expression in response to vaccination. J Immunol 167: 1809-1820.
57. Panelli MC, Riker A, Kammula US, Lee K-H, Wang E, Rosenberg SA, Marincola FM. 2000. Expansion of tumor/T cell pairs from fine needle aspirates (FNA) of melanoma metastases. J Immunol 164(1): 495-504.
58. Panelli MC, Wang E, Phan G, Puhlman M, Miller L, Ohnmacht GA, Klein H, Marincola FM. 2002. Genetic profiling of peripharal mononuclear cells and melanoma metastases in response to systemic interleukin-2 administration. Genome Biol 3(7): RESEARCH0035.
59. Panelli MC, Martin B, Nagorsen D, Wang E, Smith K, Monsurro' V, Marincola FM. 2003. A genomic and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. Cells Tissues Organs 177(3): 124-131.
60. Panelli MC, White RL Jr, Foster M, Martin B, Wang E, Smith K, Marincola FM. 2004. Forecasting the cytokine storm following systemic interleukin-2 administration. J Transl Med 2: 17.
61. Perou CM, Sertle T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, al-Katib A, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lenning PE, Berresen-Dale A-L, Brown PO, Botstein D. 2000. Molecular portraits of human breast tumorurs. Nature 406: 747-752.
62. Pockaj BA, Sherry RM, Wei JP, Yannelli JR, Carter CS, Leitman SF, Carasquillo JA, Steinberg SM, Rosenberg SA, Yang JC. 1994. Localization of 111indium-labeled tumour infiltrating lymphocytes to tumour in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73: 1731-1737.
63. Renkvist N, Castelli C, Robbins PF, Parmiani G. 2001. A listing of human tumour antigens recognized by T cells. Cancer Immunol Immunother 50(1): 3-15.
64. Restifo NP, Marincola FM, Kawakami Y, Taubenberger J, Yannelli JR, Rosenberg SA. 1996. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 88(2): 100-108.
65. Richwald GA. 2003. Imiquimod. Drugs Today 35(7): 497-511.
66. Robertson P, Scadden DT. 2003. Immune reconstitution in HIV infection and its relationship to cancer. Hematol Oncol Clin N Am 17(3): 703-716, vi.
67. Rosenberg SA, Yang JC, Restifo NP. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat Med 10(9): 909-915.
68. Rosenberg SA, Yang JC, Schwartzentruber D, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dufour E, Schwartzberg L, Spiess P, Wunderlich J, Parkhurst MR, Kawakami Y, Seipp C, Einhorn JH, White D. 1998. Immunologic and therapeutic evaluation of a synthetic tumour associated peptide vaccine for the treatment of patients with metastatic melanoma. NatMed 4(3): 321-327.
69. Rubin JT, Adams SD, Simonis T, Lotze MT. 1991. HLA polymorphism and response to IL-2 bases therapy in patients with melanoma. Society for Biological Therapy 1991 Annual Meeting, Vol 1, p 18.
70. Salgaller ML, Marincola FM, Cormier JN, Rosenberg SA. 1996. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res 56: 4749-4757.
71. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. 2001. IFN-g and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410: 1107-1111.
72. Slingluff CL, Jr. Speiser DE. 2005. Cancer vaccines targeting multiple antigens: elucidating cancer immunobiology while developing safe and accessible approaches for therapy and prevention of cancer. J Transl Med 3: 18.
73. Smyth MJ, Godfrey DI, Trapani JA. 2001. A fresh look at tumour immunosurveillance and immunotherapy. Nat Immunol 2(4): 293-299.
74. Szyf M, Pakneshan P, Rabbani SA. 2004. DNA methylation and breast cancer. Biochem Pharmac 68(6): 1187-1197.
75. Takahashi M, Yang XJ, Sugimura J, Backdahl J, Tretiakova M, Qian CN, Gray SG, Knapp R, Anema J, Kahnoski R, Nicol D, Vogelzang NJ, Furge KA, Kanayama H, Kagawa S, Teh BT. 2003. Molecular subclassification of kidney tumours and the discovery of new diagnostic markers. Oncogene 22(43): 6810-6818.
76. Timmerman JM, Levy R. 2004. Correspondence 2: cancer vaccines: pessimism in check. Nat Med 10(12): 1279.
77. t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der KK, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. 2002. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871): 530-536.
78. Ulrich C, Schmook T, Sachse MM, Sterry W, Stockfleth E. 2004. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients, Dermatol Surg 30(4 Pt 2): 622-627.
79. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. 2003. Mechanisms unerlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol 139(10): 1325-1332.
80. Vanderlugt CL, Miller SD. 2002. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol 2(2): 85-95.
81. Wang E, Marincola FM. 2000. A natural history of melanoma: serial gene expression analysis. Immunol Today 21(12): 619-623.
82. Wang E, Marincola FM. 2001. cDNA microarrays and the enigma of melanoma immune responsiveness. Cancer J 7(1): 16-23.
83. Wang E, Panelli MC, Marincola FM. 2003. Genomic analysis of cancer. Princ Pract Oncol 17(9): 1-16.
84. Wang E, Marincola FM, Stroncek D. 2005. Human leukocyte antigen (HLA) and Human Neutrophil Antigen (HNA) systems. In Hoffman R, Benz EJ, Shattil SJ, Furie B, Cohen HJ, Silberstein LE, McGlave P (eds), Hematology: Basic Principles and Practice, 4th edn. Elsevier Science: Philadelphia, PA; 2401-2432.
85. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Petersen D, Zhao Y, Simon R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg SA, Marincola FM. 2002. Prospective molecular profiling of subcutaneous melanoma metastases suggests classifiers of immune responsiveness. Cancer Res 62: 3581-3586.
86. Wang E, Adams S, Zhao Y, Panelli MC, Simon R, Klein H, Marincola FM. 2003. A strategy for detection of known and unknown SNP using a minimum number of oligonucleotides. J Transl Med 1: 4.
87. Wang E, Lichtenfels R, Bukur J, Ngalame Y, Panelli MC, Seliger B, Marincola FM. 2004a. Ontogeny and oncogenesis balance the transcriptional profile of renal cell cancer. Cancer Res 64(20): 7279-7287.
88. Wang E, Panelli MC, Monsurro' V, Marincola FM. 2004b. Gene expression profiling of anti-cancer immune responses. Curr Opin Mol Ther 6(3): 288-295.
89. Wang E, Panelli MC, Zavaglia K, Mandruzzato S, Hu N, Taylor PR, Seliger B, Zanovello P, Freedman RS, Marincola FM. 2004c. Melanoma-restricted genes. J Transl Med 2: 34.
90. Wolfel T, Klehmann E, Muller C, Schutt KH, Meyer zum Buschenfelde KH, Knuth A. 1989. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens. J Exp Med 170: 797-810.
91. Yang JC, Rosenberg SA. 1997. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer. [See comments. ] Cancer J Sci Am 3(suppl. 1): S79-84.
92. Young AN, Amin MB, Moreno CS, Lim SD, Cohen C, Petros JA, Marshall FF, Neish AS. 2001. Expression profiling of renal epithelial neoplasms: a method for tumour classification and discovery of diagnostic molecular markers. Am J Pathol 158(5): 1639-1651.